The treatment for Simon Goodrich’s disease has been costing $12,000 a month, but there has been a huge development.

Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, ...

The drug is mutation-agnostic, and the company observes no toxicity-limiting... at 06:50 FDA Grants Priority Review to Merck's Application for WELIREG® (belzutifan ... The global stock images market ...

and in combo with Welireg, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, in RCC. Importantly, Exelixis maintains all global commercial and marketing rights to its drug. A Phase 3 ...

Frontline therapy with belzutifan (Welireg) in combination with cabozantinib (Cabometyx ... enhanced clinical benefits to patients with ccRCC compared with using either drug in isolation,” ...

The FDA has accepted Merck's (MRK) supplemental NDA with priority review for its drug Welireg for the treatment of a rare ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...

Merck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral HIF-2α inhibitor, Welireg (belzutifan), for a new indication. The sNDA is ...